National Bank of Canada FI Lowers Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

National Bank of Canada FI trimmed its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 41.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,000 shares of the company’s stock after selling 50,000 shares during the period. National Bank of Canada FI owned 0.14% of 4D Molecular Therapeutics worth $768,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in FDMT. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth about $40,000. Values First Advisors Inc. purchased a new stake in 4D Molecular Therapeutics in the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. increased its stake in shares of 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $108,000. Finally, Quest Partners LLC boosted its position in shares of 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Down 5.5 %

Shares of FDMT stock opened at $6.50 on Friday. The stock has a market capitalization of $300.48 million, a P/E ratio of -2.28 and a beta of 2.74. The firm’s 50 day moving average is $8.09 and its 200 day moving average is $14.54. 4D Molecular Therapeutics, Inc. has a 12-month low of $6.41 and a 12-month high of $36.25.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada lowered their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Leerink Partners reissued an “outperform” rating and set a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Morgan Stanley assumed coverage on shares of 4D Molecular Therapeutics in a report on Thursday, November 21st. They issued an “underweight” rating and a $8.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.